Jan 30, 2019 05:02 PM IST
- Jan 30, 2019 04:57 PM IST
- Jan 23, 2019 03:27 PM IST
According to an announcement made by Torrent to the US Food and Drug Administration on January 22, the impurity detected in the API is N-nitrosodiethylamine (NDEA).
- Jan 17, 2019 11:39 AM IST
It can be bought at current levels and on dips to Rs 1,860 with a stop loss below Rs 1,780 for the target of Rs 2,050, says Ashish Chaturmohta of Sanctum Wealth Management.
- Jan 17, 2019 10:00 AM IST
On the upside, the index has resistance zone in the region of 10840-10870 levels. But, crossing above 11000 levels on a sustainable basis will confirm the uptrend.
- Nov 30, 2018 11:40 AM IST
The issued unsecured redeemable non-convertible debentures were worth Rs 500 crore.
- Nov 13, 2018 05:07 PM IST
ICICI Direct is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated November 05, 2018.
- Nov 03, 2018 05:42 PM IST
Torrent Pharma said 7 ANDAs were filed during the quarter. As on September 2018, 35 ANDAs are pending approval and 5 tentative approvals have been received, it added.
- Aug 21, 2018 07:42 PM IST
The voluntarily recall of Valsartan/Amlodipine/HCTZ tablets to the consumer level is due to the detection of trace amounts of an unexpected impurity found.
- Aug 03, 2018 11:39 AM IST
Torrent Pharmaceuticals has reported a consolidated total income from operations of Rs 1,872.00 crore and a net profit of Rs 163.00 crore for the quarter ended Jun-2018
- Aug 02, 2018 07:02 PM IST
Torrent Pharma bought domestic formulation business of Unichem Laboratories Rs 3600 crore in December 2017.
- Jul 18, 2018 03:54 PM IST
Net Sales are expected to increase by 30.2 percent Y-o-Y (up 3.9 percent Q-o-Q) to Rs. 1,789.1 crore, according to Kotak.
- Jul 13, 2018 05:02 PM IST
Edelweiss recommended hold rating on Torrent Pharmaceuticals with a target price of Rs 1333 in its research report dated July 11, 2018.
- Jun 15, 2018 09:43 PM IST
According to the bulk deal data available with the BSE, the foreign investor disposed of 9.01 lakh shares, amounting to 0.53 percent stake in the drug firm.
- Jun 12, 2018 02:43 PM IST
Edelweiss recommended hold rating on Torrent Pharmaceuticals with a target price of Rs 1333 in its research report dated May 31, 2018.
- Jun 11, 2018 05:13 PM IST
Khambatta Securities is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1485 in its research report dated May 31, 2018.
- Apr 16, 2018 06:54 PM IST
Net Sales are expected to increase by 11.5 percent Y-o-Y (up 8.3 percent Q-o-Q) to Rs. 1,599.4 crore, according to Edelweiss.
- Mar 01, 2018 06:03 PM IST
Torrent Pharmaceuticals on Thursday said it has received shareholders' nod to enhance borrowing limit from Rs 10,000 crore to Rs 15,000 crore.
- Feb 08, 2018 10:08 PM IST
The company had reported the net profit of Rs 234 crore in the same period last year.
- Jan 25, 2018 03:25 PM IST
As per a BSE filing, the Board also approved "issuance of unsecured/secured redeemable non-convertible debentures/bonds by way of private placement for an amount not exceeding Rs 12,500 crore".
- Jan 18, 2018 08:45 PM IST
Drug firm Torrent Pharmaceuticals today said it has acquired US-based generic pharmaceuticals and OTC firm Bio-Pharm Inc for an undisclosed amount.
- Dec 15, 2017 03:52 PM IST
The company has issued non-convertible debentures for an amount of Rs 1,000 crore on December 14, 2017, Torrent Pharmaceuticals said in a filing to BSE.
- Dec 14, 2017 03:52 PM IST
The transaction is in pursuance of the definitive binding agreement entered into between Torrent and Unichem on November 3, 2017, it added.
- Nov 14, 2017 04:51 PM IST
Edelweiss is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1390 in its research report dated November 06, 2017.
- Nov 07, 2017 12:19 PM IST
In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.